2020
Abstract 5509: Breaking the paradox breakers - RAF inhibitor mechanisms
Mendiratta G, McFall T, Stites E. Abstract 5509: Breaking the paradox breakers - RAF inhibitor mechanisms. Cancer Research 2020, 80: 5509-5509. DOI: 10.1158/1538-7445.am2020-5509.Peer-Reviewed Original ResearchSW48 colon cancer cellsMechanism of PAColon cancer cellsParadoxical activationRaf activationAmerican Association for Cancer ResearchATP-competitive inhibitorsDimer stabilityDownstream signalingUpstream mutationsOnco-proteinRafInhibitor mechanismCancer cellsV600 mutationMutationsRegulatory processesDriver mutationsMelanoma cellsSide effectsCombined treatmentPotential PAProteinDrug bindingNo PA
2012
Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001
Barrett M, Lenkiewicz E, Evers L, Holley T, Aziz M, Kiefer J, Maitra A, Hidalgo M, Kumar R, Hlavacek W, Stites E, Posner R, Ramanathan R, Von Hoff D. Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001. Cancer Research 2012, 72: 3697-3697. DOI: 10.1158/1538-7445.am2012-3697.Peer-Reviewed Original ResearchComparative genomic hybridizationPhase II studyStudies of therapyMolecular profilingTreating metastatic pancreatic cancerK-rasPanel of xenograftsAneuploid tumour cell populationsMetastatic pancreatic cancerComparative genomic hybridization arrayAmerican Association for Cancer ResearchTherapeutic targetK-ras mutationsTumor cell populationGene expression microarray analysisExpression microarray analysisFocal ampliconsMetastatic lesionsMetastatic biopsiesC-kitGenomic hybridizationPancreatic cancerTumor nucleiHomozygous deletionDrug sensitivityAbstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium
Ramanathan R, Barrett M, Weiss G, Posner R, NV R, Jameson G, Demeure M, Hoering A, Stites E, Maitra A, Fulk M, Hidalgo M, Von Hoff D. Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium. Cancer Research 2012, 72: lb-221-lb-221. DOI: 10.1158/1538-7445.am2012-lb-221.Peer-Reviewed Original ResearchMetastatic pancreatic cancerPhase II studyMolecular profilingPercutaneous biopsyPerformance statusPancreatic cancerNon-cross-resistant regimenOutcome of salvage therapyPatients treated with FOLFIRIRefractory metastatic pancreatic cancerMetastatic pancreatic cancer patientsSurvival rateTreating metastatic pancreatic cancerAdequate bone marrowAdequate performance statusAneuploid tumour cell populationsYear survival rateAmerican Association for Cancer ResearchEfficacy of therapyFactors of patientsTumor cell populationLong-term survivalInsufficient tumorSalvage therapyStudies of therapyAbstract 5104: Identification of key tumorigenic pathways in pancreatic adenocarcinoma patients using massively parallel DNA and RNA sequencing
Liang W, Craig D, Carpten J, Borad M, Demeure M, Weiss G, Kiefer J, Posner R, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Baker A, Han H, Lake D, Stites E, Ramanathan R, Fonseca R, Stewart A, Hoff D. Abstract 5104: Identification of key tumorigenic pathways in pancreatic adenocarcinoma patients using massively parallel DNA and RNA sequencing. Cancer Research 2012, 72: 5104-5104. DOI: 10.1158/1538-7445.am2012-5104.Peer-Reviewed Original ResearchNext-generation sequencing technologiesWhole-genome sequencingWhole-transcriptome sequencingPancreatic adenocarcinoma patientsChromosomal copy number variantsMassively parallel DNACopy number variantsPancreatic cancer pathwayAdenocarcinoma patientsPancreatic adenocarcinomaGlobal pathway analysisGenome sequenceSequencing technologiesTranscriptome sequencingPinpointing genesAmerican Association for Cancer ResearchKRAS signaling pathwayMultiple genesPoint mutationsRNA sequencingParallel DNASomatic eventsPathway analysisSignaling pathwayCancer pathways